Skeletal effects of erythropoietin in hemodialysis patients

International Urology and Nephrology

Volumn 35, Issue 3, 2003, Pages 407-413

  Takenaka, Tsuneo ^a   Itaya, Yoshiaki ^b   Ishikawa, Ichiro ^c   Kobayashi, Kenji ^d   Tsuchiya, Yoshitsugu ^b  

^a Shinjuku Suimei Clinic   (Japan)

^b Tsuchiya Clinic   (Japan)

^c Bantyo Togozaka Clinic   (Japan)

^d Kokubunji Minami guchi Clinic   (Japan)

Author keywords

1,25 dihydroxy vitamin D; Alkali phosphatase; Bone remodeling; Erythropoietin; Hemodialysis; Osteocalcin

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM CARBONATE; CREATININE; HEPARIN; IRON; OSTEOCALCIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN BINDING PROTEIN;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DATA ANALYSIS; DOSE RESPONSE; DRUG MECHANISM; HEMODIALYSIS PATIENT; HUMAN; IRON BLOOD LEVEL; KIDNEY DISEASE; MALE; MEASUREMENT; METACARPAL BONE; MODULATION; MUSCULOSKELETAL SYSTEM PARAMETERS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; ANALYSIS OF VARIANCE; BLOOD ANALYSIS; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DENSITOMETRY; DRUG ADMINISTRATION; DRUG EFFECT; IRON DEFICIENCY ANEMIA; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANEMIA, HYPOCHROMIC; BLOOD CHEMICAL ANALYSIS; BONE DENSITY; CASE-CONTROL STUDIES; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 3042802245     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:UROL.0000022950.00626.e4     Document Type: Article

References (26)

1. Levin NW. Quality of life and hematocrit level. Am J Kidney Dis 1992; 20 (Suppl 1): 16-20.
2. Daugirdas JT, Ing TS. Special problems in the dialysis patient. In: Daugirdas, JT, Ing TS, ed. Handbook of Dialysis, Part IV. Toronto/Boston: Little Brown Company, 1988: 279-448.
3. Brown EM, Gamba G, Riccardl D et al. Cloning and characterization of an extracellular Ca-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
4. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14 (Suppl 2): 22-28.
5. Wintrobe MM. Normal hematopoietic system. In: Wintrobe MM, ed. Clinical Hematology, Part II. Philadelphia: Lea & Febiger, 1981: 33-192.
6. Mullan RN, McKeveney PJ, Hodges VM et al. The ERIC genes, a novel gene family providing new insights into erythropoietin action. J Am Soc Nephrol 2000; 11: 625A (abstract).
7. Koya T, Narita J, Honda S et al. Erythropoietin induces the expression of c-kit progenitors for myeloid and erythroid cells, but not for lymphoid cells, in the bone marrow and liver. Eur J Hematol 1999; 63: 306-312.
8. Barrett JD, Zhang Z, Zhu JH et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998; 16: 1749-1757.
9. Digicayioglu M, Bichet S, Marti HH et al. Localization of specific erythropoietin binding sites in defined area of the mouse brain. Proc Natl Acad Sci USA 1995; 92: 3717-3720.
10. Lee MY, Fukunaga R, Lee TJ et al. Bone modulation in sustained hematopoietic stimulation in mice. Blood 1991; 77: 2135-2141.
11. Gregory RC, Lord KA, Panek LB et al. Subtraction cloning and initial characterization of novel epo-immediate response genes. Cytokine 2000; 12: 845-857.
12. Suda T, Takahashi H, Udagawa N et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
13. Lai YH, Tsai JC, Chen HC et al. Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism. Nephron 1995; 70: 223-228.
14. Saatci U, Topaloglu R, Ozen S et al. Does erythropoietin have a beneficial effect on calcium, phosphorus and parathyriod hormone level in pediatric hemodialysis patients? Nephron 1994; 67: 371-372.
15. Takenaka T, Takahashi K, Kobayashi T et al. Oxidized low density lipoprotein as a marker of atherosclerosis in hemodialysis patients. Clin Nephrol 2002; 58: 33-37.
16. Jilka RL, Hangoc G, Girasole G et al. Increased osteoclast development after estrogen loss: Mediation by interleukin 6. Science 1992; 257: 88-91.
17. Concensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650.
18. Takenaka T, Tsuchiya Y, Suzuki H. High performance hemodiafiltration and blood pressure stability. Nephron 1997; 75: 30-35.
19. Statopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in urentic patients. J Clin Invest 1984 ; 74: 2136-2143.
20. Druske TB. Modulating factors in the hematopoietic response to erythropoietin. Am J Kidney Dis 1991; 18 (Suppl 1): 87-92.
21. Jehle PM, Ostertag A, Schulten K et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000; 57: 423-436.
22. Sebastian A, Harris ST, Ottaway JH et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 1994; 330: 1776-1781.
23. Bourrin S, Ammann P, Bonjour JP, Rizzoli R. Dietary protein restriction lowers plasma insulin-like growth factor-I (IGF-I), impairs cortical bone formation, and induces osteoblastic resistance to IGF-I in adult female rats. Endocrinology 2000; 141: 3149-3155.
24. Bellido T, Jilka RL, Boyce BF et al. Regulation of interleukin-6, osteoclastogenlesis, and bone mass by androgens: The role of the androgen receptor. J Clin Invest 1995; 95: 2886-2895.
25. Majdan M, Kotarski J, Ksiazek A, Grzebalska A. Relationship between some prognostic markers of HD patients and serum erythropoietin, insulin-like growth factor-1, leptin, parathyrmone and teststerone. Int Urol Nephrol 1999; 31: 563-569.
26. Urena P, Bonnardeaux A, Eckardt KU et al. Insulin-like growth factor I: A modulator of erythropoiesis in uremic patients? Nephrol Dial Transplant 1992; 7: 40-44.